Boston Scientific Corporation
A quality franchise priced for a two-engine stall

Research date: 31 October 2026. Company: Boston Scientific Corporation (Marlborough, Massachusetts). Listing: NYSE, BSX, USD. CIK 885725; ISIN US1011371077. Reporting currency: USD (US GAAP). Latest financial period reviewed: quarter ended 30 September 2026 (Q3 release and Financial and Operational Highlights deck, 28 October 2026; the Q3 10-Q was not yet on EDGAR at capture). Material announcements reviewed through 30 October 2026. Capture window 31 October 2026, 14:30 to 15:30 Europe/Luxembourg (+01:00).

Tags used throughout: confirmed = company filing, release or primary source; est. = our arithmetic from confirmed inputs; speculated = sell-side, aggregator, news or social source. Every figure carries the source's own date; market data carries a capture timestamp as well.

Why this company is on the research list

Boston Scientific was one of the best compounders in large-cap medtech into 2025: sales reached USD 20.07B in 2025 (confirmed, 10-K filed 17 Feb 2026), up from USD 14.24B in 2023, and adjusted EPS reached USD 3.06 (confirmed, Q4 2025 release, 4 Feb 2026). The share price peaked near USD 105 in November 2025 and closed at USD 41.98 on 30 October 2026 (Yahoo chart API, captured 31 Oct 15:00), a fall of about 60% while reported sales kept rising. A drop of that size in a business of this quality is the question this memo tries to answer: is the market pricing a permanent loss of the two growth engines (pulsed field ablation and Watchman), or a temporary stall plus a one-off cyber outage?

Investment memo: our current view

Quality at a value multiple, with no near-term catalyst and an acquisition still to close. The franchise is intact outside two businesses. In Q3 2026 Interventional Cardiology and Vascular Therapies grew 12% and Neuromodulation 13% (confirmed, 28 Oct 2026). But the two engines that carried 2024 and 2025 have both turned: Electrophysiology fell 5.3% organic to USD 816M and Watchman fell 5.9% to USD 482M (confirmed). Pulsed field ablation (PFA) is now 80% to 85% of US ablation procedures, so the conversion tailwind is spent, and Medtronic, Johnson & Johnson and Abbott have taken share (company comments reported by MedTech Dive, 29 Jul 2026; share figures speculated). Watchman lost part of its referral funnel after the CHAMPION-AF data (March 2026) changed which patients are sent for left atrial appendage closure (company: "changes in patient identification and referral", confirmed; trial reading speculated).

On top of that, a cyber incident on 25 August 2026 shut ordering, manufacturing and shipping for about eight business days (8-Ks of 26 Aug and 8 Sep 2026, confirmed). Management puts the Q3 cost at about 300 bps of organic growth and USD 0.07 of adjusted EPS (call, 28 Oct 2026, speculated via news summaries). Guidance has now been cut three times in 2026: reported sales growth from 10.5 to 11.5% (February) to about 4.25% (October), adjusted EPS from USD 3.43 to 3.49 to USD 3.16 to 3.18 (confirmed). The CEO said 2027 sales and EPS will be challenged to grow (MedTech Dive, 28 Oct 2026, speculated quote).

At USD 41.98 the shares trade on about 13.2x 2026 adjusted EPS and about 11.7x trailing adjusted EBITDA (est.), against a three-year average forward P/E near 26.5x (aggregator, 31 Mar 2026, speculated). Free cash flow should still be about USD 3.6B in 2026 (company estimate, confirmed), a yield near 5.9% (est.). Insiders bought into the decline: the CEO bought about 186,240 shares at USD 48.33 on 3 August 2026 and three directors bought smaller lots (Form 4s, EDGAR). The company also repurchased about 40M shares with a USD 2B accelerated buyback completed by June (confirmed).

Our scenario values today are USD 29 bust, USD 46 base, USD 72 boom (2028 adjusted EPS times a P/E, discounted two years at 9%; arithmetic below). The price sits between bust and base. TipRanks' 21-analyst average target is USD 49.85 (30 Oct 2026, speculated), and the post-Q3 broker targets we found run from USD 44 to 57. We found no Morningstar fair value through the web tools; it is left for the IBKR capture.

The next hard test is the Q4 2026 report with first 2027 guidance, expected in early February 2027 (date not yet announced; Q4 2025 was reported on 4 February 2026). Before it, the Penumbra close (expected early Q1 2027) sets how much debt the balance sheet carries into 2027.

Thesis underwriting

Listing and timestamps

What the business actually sells

Boston Scientific makes catheters, implants and single-use devices across eight businesses in two segments. From 1 January 2027 it reports three: Interventional Therapies, Rhythm Solutions and MedSurg (8-K 7 Oct 2026, confirmed).

All confirmed: Q3 2026 Financial and Operational Highlights, 28 Oct 2026, captured 31 Oct 14:50.

Where the catheter sits: one AF patient and the money that reaches Boston Scientific

The reference unit is one US atrial fibrillation patient treated with PFA ablation plus a concomitant Watchman implant, the procedure combination the company is now steering toward. Boston Scientific discloses no device prices, so every cost below is our estimate.

Money ladder (est.): 2025 Watchman sales of USD 1.96B (speculated, research summary of the Q4 2025 release; MedTech Dive 28 Oct 2026 gives only the near 30% growth) at about USD 11.5k per device is about 170,000 implants a year worldwide. 2025 EP sales of USD 3.33B (speculated, transcript summary) at about USD 10k per case is about 330,000 cases. The company deck sizes complex-arrhythmia ablation at USD 3B+, so one point of US PFA share is worth roughly USD 25 to 35M of annual sales. The closing comparison: losing ten points of US PFA share costs about USD 300M of sales, about 1.5% of group revenue. The EP slowdown hurts the growth rate far more than it hurts the size of the company.

The financial starting point

Quarterly trend 2026: Q1 sales about USD 5.20B (est. as 9M less Q2 and Q3; +11.6% reported), Q2 USD 5.44B (+7.5%), Q3 USD 5.14B (+1.5%), Q4 guide -3% to -1% (about USD 5.13 to 5.23B, est.). Adjusted gross margin fell 300 bps to 68.0% in Q3 and adjusted operating margin 150 bps to 26.5% (confirmed). Days sales outstanding rose from 51 to 56 and inventory days stand at 178 (confirmed), consistent with orders shipped late after the outage.

Balance sheet at 30 September 2026: debt USD 11.95B, LTM adjusted EBITDA USD 6.19B, 1.9x (confirmed, deck appendix C). Cash was USD 539M at 30 June (10-Q, confirmed); the 30 September figure awaits the 10-Q. Stockholders' equity USD 24.9B and goodwill USD 18.6B at 30 June (confirmed).

Restructuring: a 2026 plan approved on 21 July 2026 costs USD 700 to 800M pre-tax (USD 600 to 700M cash) through 2029 and targets about USD 500M of annual gross savings, a substantial portion to be reinvested (8-K 27 Jul 2026, confirmed).

Competitors and market share (31 October 2026)

Share anchors: PFA was about 70% of US ablation and close to 50% globally at end 2025 (Q4 2025 call, speculated via transcript summaries) and 80 to 85% of US procedures by July 2026 (MedTech Dive, 29 Jul 2026, speculated). Neither figure is Boston Scientific's own PFA share; we found no primary source for that number. The company sizes its 2026 served market at about USD 75B growing about 7% (deck, confirmed).

Scenarios: 2028 earnings and 2030 revenue under bust, base and boom (31 October 2026)

Start: 2026 sales about USD 20.9B (est. from guidance), adjusted EPS USD 3.17 (guidance midpoint, confirmed), plus about USD 1.5B of Penumbra sales from 2027 (est.).

Arithmetic (all est.): 2030 revenue = (20.9 + 1.5) x (1 + g)^4. Base EPS path: 2027 about flat at USD 3.15 (cyber add-back +0.07, Penumbra dilution -0.07, EP and Watchman drag as management describes), then about 8% in 2028 from restructuring savings and Penumbra integration. Discount factor 1.09^2 = 1.188, so base value today = 3.40 x 16 / 1.188 = 54.4 / 1.188 = USD 45.8. Bust assumes EP keeps losing share and Watchman declines through 2028. Boom needs EP back to market growth with FARAPOINT and OPAL mapping, concomitant Watchman growth and a partial return toward the historical multiple. The single driver of the boom case is US EP share. Against consensus: the post-Q3 targets (USD 44 to 57) sit around our base case; none we found are near the boom case.

Valuation: market data and scenario values as of 30 October 2026 close

Peer forward multiples were not captured from a dated primary source; they are left for the IBKR pass.

Penumbra deal arithmetic

Terms (announced 15 Jan 2026, joint release on EDGAR, confirmed): USD 374 per Penumbra share in cash or 3.8721 BSX shares, prorated to about 73% cash and 27% stock; enterprise value about USD 14.5B; USD 0.06 to 0.08 dilutive to adjusted EPS in the first full year. With BSX at USD 41.98 the stock leg is worth 3.8721 x 41.98 = USD 162.55, so the blended value is 0.73 x 374 + 0.27 x 162.55 = USD 316.9 (est.), against a Penumbra close of USD 318.95 (30 Oct 2026, Yahoo). The visible Penumbra discount to USD 374 is almost all BSX's own fall, not doubt about the close. New BSX shares: about 38.8M Penumbra shares (14.5B / 374, est.) x 27% x 3.8721 = about 40M (est., 2.8% dilution). New debt about USD 11B (speculated, press); pro forma leverage about (11.95 + 11) / (6.19 + 0.3) = about 3.5x (est.; Penumbra EBITDA of 0.3B speculated).

Dilution and capital return history

Scenario values per share today

Bust USD 29.3, base USD 45.8, boom USD 72.2, against the price of USD 41.98 and the TipRanks consensus of USD 49.85. The base case is the value carried into FAIR_VALUE.json.

IBKR ratings

Fair value update (31 Oct 2026, after this capture): the average shown on the price chart is now USD 50.43, 20.1% above the 2026-10-30 close of 41.98 (green). Inputs: Morningstar fair value via IBKR Mobile (Analyst Equity Report; 4 stars, moat Narrow, uncertainty Medium) 49.0 (2026-10-28); LSEG (Refinitiv) consensus target, 33 analysts, via IBKR Mobile 56.5 (2026-10-31); The Claude Trader base case 45.8 (2026-10-31). Where an earlier section quotes a different average, this one is current.

Captured 2026-10-31 15:38 to 15:40 Europe/Luxembourg from IBKR Mobile (read-only). Full table with screenshots: ibkr/ibkr_bsx_2026-10-31.md.

Latest IBKR news: - 30 Oct 2026 Dow Jones / Benzinga: TD Cowen cuts Boston Scientific to Hold from Buy, target 46 from 56

Leadership and governance (31 October 2026)

Who runs it

• Mike Mahoney, chairman and CEO. Hired, not a founder. Joined as president in 2011 from Johnson & Johnson's medical devices and diagnostics group after a career at GE Healthcare; CEO since November 2012, succeeding Ray Elliott, who retired; chairman since 2016. (From company leadership pages and proxy history, not re-fetched this session, so tagged speculated until the 2026 proxy is read.) The 2026 guidance cuts are the first sustained miss of his tenure.
• Joe Fitzgerald, promoted to EVP and chief operating officer from 1 Jan 2027, base salary USD 1.05M, bonus target 110% of salary (8-K 7 Oct 2026, confirmed). At the company since 1990; ran Cardiovascular since May 2022. A COO appointment under a long-serving CEO is often a succession step (speculated).
• Arthur Butcher, EVP and group president MedSurg and Asia Pacific, retires 1 Jan 2027 (8-K 23 Sep 2026, confirmed). Stephen Morse takes MedSurg and Asia Pacific, Lance Bates leads Interventional Therapies (including Penumbra), Nick Spadea-Anello leads Rhythm Solutions (8-K 7 Oct 2026, confirmed).

Promises versus delivery in 2026

Every quarter of 2026 lowered the year. Q2 itself beat its own guide (7.0% organic vs 5 to 7%), so the misses come from forecasting EP and Watchman, then from the outage.

Revenue-quality test

• Growth concentration: in 2025 EP (USD 3.33B, +73% organic, speculated via transcript summary) and Watchman (USD 1.96B, +29%, speculated via research summary) were about 26% of sales but most of the growth. Both now decline.
• The rest of the business grows about 6% (company comment, July 2026, speculated quote); ICVT +12% in Q3 (confirmed).
• Geography Q3 2026: US 64% of sales (+0.5%), EMEA +6.1% operational, APAC -1.1% (China volume-based procurement), LACA +10.5% (confirmed).
• Working capital: DSO up to 56 days from 51 (confirmed) after the outage; watch whether it normalises in Q4.
• Non-GAAP gap: Q3 GAAP EPS USD 0.40 vs adjusted USD 0.73. Amortization (USD 0.14), restructuring (0.05), acquisition (0.04) and litigation (0.04) charges are excluded (confirmed). Litigation charges of USD 157M in 9M 2026 against nil a year earlier need the 10-Q note.

Insider register (Form 4s, EDGAR, located via search index, captured 31 Oct 14:55)

The CEO's purchase (about USD 9M) is large for a hired CEO, and all four buys were above today's price. We did not check for later Form 4 sales.

Red flags

• Cyber incident (25 Aug 2026): material to Q3 and FY 2026 results, investigation ongoing; the company says no material long-term impact (8-K 8 Sep 2026, confirmed). Any litigation or regulatory follow-up is unknown.
• Accolade pacemaker battery issue: FDA correction in the most serious class; 4 deaths and 2,557 serious injuries reported as of 18 Mar 2026; the fix is a software update; a New York Times report (March 2026) said the problem was known for years; product-liability class investigations announced (FDA notice confirmed, the rest speculated).
• Three guidance cuts in one year, the third with a 2027 "challenged to grow" comment.
• Watchman evidence: CHAMPION-AF reportedly showed slightly more ischaemic strokes with Watchman FLX than with anticoagulants (press summaries, speculated; the primary paper should be read before relying on it).
• No restatements, auditor change or delayed filings found.

Next dated hard test

1. Penumbra close, expected early Q1 2027 (company, 28 Oct 2026): financing terms set 2027 interest cost and leverage.
2. Q4 2026 results and first 2027 guidance, expected early February 2027 (not yet announced; Q4 2025 was reported on 4 February 2026). Pass marks: Q4 sales inside -3% to -1%, US EP and US Watchman sequentially stable, DSO back near 51 days, 2027 adjusted EPS guidance at or above flat including Penumbra.

Fact audit (31 October 2026)

Self-audit by the author; the separate fork audit of template step 2 has not run yet and its corrections will be recorded here.

Fact-audit notes (adversarial audit, 31 October 2026)

Independent re-check against the Q3 2026 release and highlights deck (28 Oct 2026), Q2 release (29 Jul 2026), 8-Ks of 18 May, 21 Jul, 7 Sep, 21 Sep and 7 Oct 2026, Penumbra deal release (15 Jan 2026), CEO Form 4 (3 Aug 2026), Yahoo chart meta and MedTech Dive (28 Oct 2026), captured 31 Oct 2026 15:20 to 15:40 +01:00. All segment sales and growth rates, guidance ranges, margins, DSO and DIOH, debt and 1.9x leverage, cash-flow lines, share counts, 52-week range, restructuring plan, ASR (about 40M shares), officer changes, Penumbra terms and the CEO buy (186,240 at USD 48.3323, 1,590,024 held) were confirmed; every valuation and scenario computation was recomputed and matches.

What is still open

• Morningstar fair value, moat and uncertainty; LSEG consensus (IBKR pass).
• Cash at 30 September 2026 and the litigation note (Q3 10-Q, due early November).
• Penumbra regulatory status and financing.
• Primary CHAMPION-AF and OPTION readings.

Information dates and future updates

Prices through the 30 October 2026 close; company data through the Q3 release of 28 October 2026; analyst targets through 30 October 2026. Review after the Q3 10-Q and again after the Q4 report.

Sources

• Q3 2026 earnings release, 8-K 28 Oct 2026: https://www.sec.gov/Archives/edgar/data/885725/000088572526000066/earningsrelease_live.htm
• Q3 2026 Financial and Operational Highlights: https://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR-V3/FOH/q3-2026-foh.pdf
• Q2 2026 earnings release, 8-K 29 Jul 2026: https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/q22026earningsrelease.htm
• Cyber 8-Ks of 26 Aug and 8 Sep 2026, restructuring 8-K of 27 Jul 2026, officer 8-Ks of 23 Sep and 7 Oct 2026 (EDGAR, CIK 885725)
• ASR and MiRus releases, 18 May 2026 (EDGAR)
• Penumbra deal release, January 2026: https://www.sec.gov/Archives/edgar/data/885725/000094787126000034/ss5822817_ex9901.htm
• MedTech Dive, 28 Oct 2026: https://www.medtechdive.com/news/boston-scientific-cuts-2026-guidance-for-third-time-this-year/873037/
• MedTech Dive, 29 Jul 2026: https://www.medtechdive.com/news/boston-scientific-again-cuts-2026-guidance/826473/
• TipRanks forecast, 30 Oct 2026: https://www.tipranks.com/stocks/bsx/forecast
• MarketBeat price targets, 30 Oct 2026: https://www.marketbeat.com/stocks/NYSE/BSX/price-target/
• FDA Accolade correction: https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/pacemaker-correction-boston-scientific-issues-correction-accolade-pacemakers-and-crt-ps
• Yahoo Finance chart API, BSX daily closes